nodes	percent_of_prediction	percent_of_DWPC	metapath
Entecavir—Skin disorder—Pentoxifylline—systemic scleroderma	0.00346	0.00346	CcSEcCtD
Entecavir—Renal failure—Leflunomide—systemic scleroderma	0.00343	0.00343	CcSEcCtD
Entecavir—Hyperglycaemia—Mycophenolic acid—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Entecavir—Alopecia—Captopril—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Entecavir—Haematuria—Leflunomide—systemic scleroderma	0.00333	0.00333	CcSEcCtD
Entecavir—Hepatobiliary disease—Leflunomide—systemic scleroderma	0.0033	0.0033	CcSEcCtD
Entecavir—Pancreatitis—Lisinopril—systemic scleroderma	0.0033	0.0033	CcSEcCtD
Entecavir—Renal failure—Mycophenolic acid—systemic scleroderma	0.00327	0.00327	CcSEcCtD
Entecavir—Insomnia—Pentoxifylline—systemic scleroderma	0.00322	0.00322	CcSEcCtD
Entecavir—Blood creatinine increased—Mycophenolate mofetil—systemic scleroderma	0.00319	0.00319	CcSEcCtD
Entecavir—Haematuria—Mycophenolic acid—systemic scleroderma	0.00317	0.00317	CcSEcCtD
Entecavir—Somnolence—Pentoxifylline—systemic scleroderma	0.00317	0.00317	CcSEcCtD
Entecavir—Hepatobiliary disease—Mycophenolic acid—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Entecavir—Neutropenia—Lisinopril—systemic scleroderma	0.00314	0.00314	CcSEcCtD
Entecavir—Dyspepsia—Pentoxifylline—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Entecavir—Hepatitis—Leflunomide—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Entecavir—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.00312	0.00312	CcSEcCtD
Entecavir—Oedema peripheral—Leflunomide—systemic scleroderma	0.00308	0.00308	CcSEcCtD
Entecavir—Anaphylactic shock—Mometasone—systemic scleroderma	0.00307	0.00307	CcSEcCtD
Entecavir—Infection—Mometasone—systemic scleroderma	0.00305	0.00305	CcSEcCtD
Entecavir—Hyperglycaemia—Lisinopril—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Entecavir—Immune system disorder—Azathioprine—systemic scleroderma	0.00299	0.00299	CcSEcCtD
Entecavir—Hepatitis—Mycophenolic acid—systemic scleroderma	0.00299	0.00299	CcSEcCtD
Entecavir—Renal failure—Lisinopril—systemic scleroderma	0.00295	0.00295	CcSEcCtD
Entecavir—Oedema peripheral—Mycophenolic acid—systemic scleroderma	0.00294	0.00294	CcSEcCtD
Entecavir—Alopecia—Azathioprine—systemic scleroderma	0.00293	0.00293	CcSEcCtD
Entecavir—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00291	0.00291	CcSEcCtD
Entecavir—Pancreatitis—Mycophenolate mofetil—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Entecavir—Haematuria—Lisinopril—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Entecavir—Hepatobiliary disease—Lisinopril—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Entecavir—Immune system disorder—Leflunomide—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Entecavir—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00282	0.00282	CcSEcCtD
Entecavir—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00282	0.00282	CcSEcCtD
Entecavir—Alopecia—Leflunomide—systemic scleroderma	0.00277	0.00277	CcSEcCtD
Entecavir—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.00275	0.00275	CcSEcCtD
Entecavir—Mental disorder—Leflunomide—systemic scleroderma	0.00274	0.00274	CcSEcCtD
Entecavir—Malnutrition—Leflunomide—systemic scleroderma	0.00273	0.00273	CcSEcCtD
Entecavir—Dyspepsia—Mometasone—systemic scleroderma	0.0027	0.0027	CcSEcCtD
Entecavir—Anaphylactic shock—Captopril—systemic scleroderma	0.0027	0.0027	CcSEcCtD
Entecavir—Hepatitis—Lisinopril—systemic scleroderma	0.00269	0.00269	CcSEcCtD
Entecavir—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Entecavir—Oedema peripheral—Lisinopril—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Entecavir—Fatigue—Mometasone—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Entecavir—Alopecia—Mycophenolic acid—systemic scleroderma	0.00264	0.00264	CcSEcCtD
Entecavir—Mental disorder—Mycophenolic acid—systemic scleroderma	0.00262	0.00262	CcSEcCtD
Entecavir—Malnutrition—Mycophenolic acid—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Entecavir—Leukopenia—Azathioprine—systemic scleroderma	0.00258	0.00258	CcSEcCtD
Entecavir—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.00258	0.00258	CcSEcCtD
Entecavir—Asthenia—Pentoxifylline—systemic scleroderma	0.00256	0.00256	CcSEcCtD
Entecavir—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00251	0.00251	CcSEcCtD
Entecavir—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.0025	0.0025	CcSEcCtD
Entecavir—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.00248	0.00248	CcSEcCtD
Entecavir—Insomnia—Captopril—systemic scleroderma	0.00244	0.00244	CcSEcCtD
Entecavir—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00244	0.00244	CcSEcCtD
Entecavir—Leukopenia—Leflunomide—systemic scleroderma	0.00244	0.00244	CcSEcCtD
Entecavir—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00244	0.00244	CcSEcCtD
Entecavir—Abdominal pain—Mometasone—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Entecavir—Body temperature increased—Mometasone—systemic scleroderma	0.00243	0.00243	CcSEcCtD
Entecavir—Somnolence—Captopril—systemic scleroderma	0.0024	0.0024	CcSEcCtD
Entecavir—Alopecia—Lisinopril—systemic scleroderma	0.00238	0.00238	CcSEcCtD
Entecavir—Dyspepsia—Captopril—systemic scleroderma	0.00238	0.00238	CcSEcCtD
Entecavir—Hepatitis—Mycophenolate mofetil—systemic scleroderma	0.00236	0.00236	CcSEcCtD
Entecavir—Mental disorder—Lisinopril—systemic scleroderma	0.00236	0.00236	CcSEcCtD
Entecavir—Dizziness—Pentoxifylline—systemic scleroderma	0.00236	0.00236	CcSEcCtD
Entecavir—Malnutrition—Lisinopril—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Entecavir—Infection—Azathioprine—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Entecavir—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00233	0.00233	CcSEcCtD
Entecavir—Fatigue—Captopril—systemic scleroderma	0.00233	0.00233	CcSEcCtD
Entecavir—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.00232	0.00232	CcSEcCtD
Entecavir—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.0023	0.0023	CcSEcCtD
Entecavir—Skin disorder—Azathioprine—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Entecavir—Vomiting—Pentoxifylline—systemic scleroderma	0.00226	0.00226	CcSEcCtD
Entecavir—Rash—Pentoxifylline—systemic scleroderma	0.00225	0.00225	CcSEcCtD
Entecavir—Dermatitis—Pentoxifylline—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Entecavir—Headache—Pentoxifylline—systemic scleroderma	0.00223	0.00223	CcSEcCtD
Entecavir—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Entecavir—Infection—Leflunomide—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Entecavir—Gastrointestinal pain—Captopril—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Entecavir—Asthenia—Mometasone—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Entecavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Entecavir—Nervous system disorder—Leflunomide—systemic scleroderma	0.00218	0.00218	CcSEcCtD
Entecavir—Skin disorder—Leflunomide—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Entecavir—Hepatic failure—Methotrexate—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Entecavir—Body temperature increased—Captopril—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Entecavir—Abdominal pain—Captopril—systemic scleroderma	0.00213	0.00213	CcSEcCtD
Entecavir—Nausea—Pentoxifylline—systemic scleroderma	0.00212	0.00212	CcSEcCtD
Entecavir—Infection—Mycophenolic acid—systemic scleroderma	0.00211	0.00211	CcSEcCtD
Entecavir—Diarrhoea—Mometasone—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Entecavir—Leukopenia—Lisinopril—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Entecavir—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Entecavir—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Entecavir—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00207	0.00207	CcSEcCtD
Entecavir—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Entecavir—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Entecavir—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Entecavir—Insomnia—Leflunomide—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Entecavir—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.00199	0.00199	CcSEcCtD
Entecavir—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00198	0.00198	CcSEcCtD
Entecavir—Dyspepsia—Leflunomide—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Entecavir—Pancreatitis—Prednisone—systemic scleroderma	0.00196	0.00196	CcSEcCtD
Entecavir—Vomiting—Mometasone—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Entecavir—Rash—Mometasone—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Entecavir—Asthenia—Captopril—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Entecavir—Dermatitis—Mometasone—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Entecavir—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Entecavir—Headache—Mometasone—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Entecavir—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Entecavir—Insomnia—Mycophenolic acid—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Entecavir—Fatigue—Leflunomide—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Entecavir—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Entecavir—Infection—Lisinopril—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Entecavir—Somnolence—Mycophenolic acid—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Entecavir—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Entecavir—Neutropenia—Prednisone—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Entecavir—Abdominal pain—Azathioprine—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Entecavir—Body temperature increased—Azathioprine—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Entecavir—Skin disorder—Lisinopril—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Entecavir—Diarrhoea—Captopril—systemic scleroderma	0.00185	0.00185	CcSEcCtD
Entecavir—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00184	0.00184	CcSEcCtD
Entecavir—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Entecavir—Fatigue—Mycophenolic acid—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Entecavir—Nausea—Mometasone—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Entecavir—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Entecavir—Hyperglycaemia—Prednisone—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Entecavir—Dizziness—Captopril—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Entecavir—Abdominal pain—Leflunomide—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Entecavir—Body temperature increased—Leflunomide—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Entecavir—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Entecavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Entecavir—Insomnia—Lisinopril—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Entecavir—Vomiting—Captopril—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Entecavir—Rash—Captopril—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Entecavir—Dermatitis—Captopril—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Entecavir—Somnolence—Lisinopril—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Entecavir—Headache—Captopril—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Entecavir—Dyspepsia—Lisinopril—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Entecavir—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Entecavir—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Entecavir—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Entecavir—Infection—Mycophenolate mofetil—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Entecavir—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Entecavir—Fatigue—Lisinopril—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Entecavir—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Entecavir—Pancreatitis—Methotrexate—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Entecavir—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Entecavir—Diarrhoea—Azathioprine—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Entecavir—Nausea—Captopril—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Entecavir—Asthenia—Leflunomide—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Entecavir—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Entecavir—Neutropenia—Methotrexate—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Entecavir—Dizziness—Azathioprine—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Entecavir—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Entecavir—Asthenia—Mycophenolic acid—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Entecavir—Diarrhoea—Leflunomide—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Entecavir—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Entecavir—Body temperature increased—Lisinopril—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Entecavir—Abdominal pain—Lisinopril—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Entecavir—Vomiting—Azathioprine—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Entecavir—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Entecavir—Rash—Azathioprine—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Entecavir—Dermatitis—Azathioprine—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Entecavir—Headache—Azathioprine—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Entecavir—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Entecavir—Dizziness—Leflunomide—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Entecavir—Renal failure—Methotrexate—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Entecavir—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Entecavir—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Entecavir—Immune system disorder—Prednisone—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Entecavir—Haematuria—Methotrexate—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Entecavir—Vomiting—Leflunomide—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Entecavir—Alopecia—Prednisone—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Entecavir—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Entecavir—Dizziness—Mycophenolic acid—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Entecavir—Rash—Leflunomide—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Entecavir—Dermatitis—Leflunomide—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Entecavir—Mental disorder—Prednisone—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Entecavir—Nausea—Azathioprine—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Entecavir—Headache—Leflunomide—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Entecavir—Malnutrition—Prednisone—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Entecavir—Asthenia—Lisinopril—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Entecavir—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Entecavir—Vomiting—Mycophenolic acid—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Entecavir—Rash—Mycophenolic acid—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Entecavir—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Entecavir—Hepatitis—Methotrexate—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Entecavir—Headache—Mycophenolic acid—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Entecavir—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Entecavir—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Entecavir—Nausea—Leflunomide—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Entecavir—Diarrhoea—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Entecavir—Dizziness—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Entecavir—Nausea—Mycophenolic acid—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Entecavir—Vomiting—Lisinopril—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Entecavir—Immune system disorder—Methotrexate—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Entecavir—Rash—Lisinopril—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Entecavir—Dermatitis—Lisinopril—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Entecavir—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Entecavir—Headache—Lisinopril—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Entecavir—Alopecia—Methotrexate—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Entecavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Entecavir—Mental disorder—Methotrexate—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Entecavir—Malnutrition—Methotrexate—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Entecavir—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Entecavir—Nausea—Lisinopril—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Entecavir—Anaphylactic shock—Prednisone—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Entecavir—Infection—Prednisone—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Entecavir—Nervous system disorder—Prednisone—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Entecavir—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Entecavir—Skin disorder—Prednisone—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Entecavir—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Entecavir—Rash—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Entecavir—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Entecavir—Headache—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Entecavir—Leukopenia—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Entecavir—Insomnia—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Entecavir—Dyspepsia—Prednisone—systemic scleroderma	0.000999	0.000999	CcSEcCtD
Entecavir—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000995	0.000995	CcSEcCtD
Entecavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000983	0.000983	CcSEcCtD
Entecavir—Fatigue—Prednisone—systemic scleroderma	0.000979	0.000979	CcSEcCtD
Entecavir—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000949	0.000949	CcSEcCtD
Entecavir—Infection—Methotrexate—systemic scleroderma	0.000943	0.000943	CcSEcCtD
Entecavir—Nervous system disorder—Methotrexate—systemic scleroderma	0.00093	0.00093	CcSEcCtD
Entecavir—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000928	0.000928	CcSEcCtD
Entecavir—Skin disorder—Methotrexate—systemic scleroderma	0.000922	0.000922	CcSEcCtD
Entecavir—Abdominal pain—Prednisone—systemic scleroderma	0.000897	0.000897	CcSEcCtD
Entecavir—Body temperature increased—Prednisone—systemic scleroderma	0.000897	0.000897	CcSEcCtD
Entecavir—Insomnia—Methotrexate—systemic scleroderma	0.000858	0.000858	CcSEcCtD
Entecavir—Somnolence—Methotrexate—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Entecavir—Dyspepsia—Methotrexate—systemic scleroderma	0.000835	0.000835	CcSEcCtD
Entecavir—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000819	0.000819	CcSEcCtD
Entecavir—Fatigue—Methotrexate—systemic scleroderma	0.000818	0.000818	CcSEcCtD
Entecavir—Asthenia—Prednisone—systemic scleroderma	0.000814	0.000814	CcSEcCtD
Entecavir—Diarrhoea—Prednisone—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Entecavir—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000776	0.000776	CcSEcCtD
Entecavir—Dizziness—Prednisone—systemic scleroderma	0.000751	0.000751	CcSEcCtD
Entecavir—Abdominal pain—Methotrexate—systemic scleroderma	0.00075	0.00075	CcSEcCtD
Entecavir—Body temperature increased—Methotrexate—systemic scleroderma	0.00075	0.00075	CcSEcCtD
Entecavir—Vomiting—Prednisone—systemic scleroderma	0.000722	0.000722	CcSEcCtD
Entecavir—Rash—Prednisone—systemic scleroderma	0.000716	0.000716	CcSEcCtD
Entecavir—Dermatitis—Prednisone—systemic scleroderma	0.000715	0.000715	CcSEcCtD
Entecavir—Headache—Prednisone—systemic scleroderma	0.000711	0.000711	CcSEcCtD
Entecavir—Asthenia—Methotrexate—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Entecavir—Nausea—Prednisone—systemic scleroderma	0.000674	0.000674	CcSEcCtD
Entecavir—Diarrhoea—Methotrexate—systemic scleroderma	0.000649	0.000649	CcSEcCtD
Entecavir—Dizziness—Methotrexate—systemic scleroderma	0.000627	0.000627	CcSEcCtD
Entecavir—Vomiting—Methotrexate—systemic scleroderma	0.000603	0.000603	CcSEcCtD
Entecavir—Rash—Methotrexate—systemic scleroderma	0.000598	0.000598	CcSEcCtD
Entecavir—Dermatitis—Methotrexate—systemic scleroderma	0.000598	0.000598	CcSEcCtD
Entecavir—Headache—Methotrexate—systemic scleroderma	0.000594	0.000594	CcSEcCtD
Entecavir—Nausea—Methotrexate—systemic scleroderma	0.000564	0.000564	CcSEcCtD
